IBRX 8-K: Fda approval
ImmunityBio
Filed with the SEC on · accession 0001326110-26-000091
IBRX filed a 8-K (current report) with the SEC on Nov 9, 2026. A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
Summary of the filing
ImmunityBio announced that ANKTIVA plus Bacillus Calmette-Guérin (BCG) met the primary endpoint in Cohort A of its BCG-naïve non-muscle invasive bladder cancer randomized QUILT-2.005 trial.
Key details
✦ Ask GOAX AI about this filing — what it means for IBRX, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for IBRX?
Click hereFrequently asked questions
What did IBRX file with the SEC on Nov 9, 2026?
IBRX filed a 8-K (Fda approval). ImmunityBio announced that ANKTIVA plus Bacillus Calmette-Guérin (BCG) met the primary endpoint in Cohort A of its BCG-naïve non-muscle invasive bladder cancer randomized QUILT-2.005 trial.
What does a fda approval mean for IBRX stock?
For a small biotech one drug can be most of the company’s value. Approval opens sales; a rejection (complete response letter) can delay it by years.
How do I read a 8-K?
A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
Other IBRX SEC filings
Get alerts when IBRX files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days